Instrument Inactif

Autres langues Mylan N.V. Nasdaq

Actions

MYL

NL0011031208

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says	18/04
UK Regulator to Consider Undertakings for Theramex-Viatris Deal	18/04
Idorsia bleibt weiter in einer finanziell schwierigen Lage	17/04
Idorsia sucht weiter nach Lösung für finanziellen Engpass	17/04
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024	16/04
Viatris Launches New Generic Treatment Option for Multiple Sclerosis in Canada	15/04
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	15/04
Viatris Appoints Corinne Le Goff as Chief Commercial Officer	15/04
Viatris Inc. Appoints Corinne Le Goff as Chief Commercial Officer	15/04
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada	15/04
Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada	15/04
Atomo Diagnostics Wins AU$570,000 HIV Self-Tests Order	15/04
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	11/04
UK's Theramex sees no impact to HRT products supply after CMA probe	05/04
Pharma deal could reduce choice and lead to higher prices for HRT treatments	04/04
UK Regulator Finds Competition Concerns in Theramex-Viatris Merger Deal	04/04
UK watchdog says Theramex-Viatris deal raises competition concerns	04/04
Viatris Announces the Launch of RYZUMVl 0.75% in the United States	02/04
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	01/04
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	01/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Mylan N.V. Nasdaq

Actions

MYL

NL0011031208

Autres langues

Filtres